2023 World Conference on Lung Cancer (Posters)-P2.10. Co-occurring Loss of CDKN2A/2B Associated with Worse Survival and Increase Risk of Brain Metastasis in ALK-Rearranged Non-small Cell Lung Cancer

P2.10. Co-occurring Loss of CDKN2A/2B Associated with Worse Survival and Increase Risk of Brain Metastasis in ALK-Rearranged Non-small Cell Lung Cancer - PDF(Slides)

Back to course

Pdf Summary

A recent study conducted in Latin American cancer centers investigated the prognostic role of concurrent genetic alterations in ALK-positive non-small cell lung cancer (NSCLC) patients treated with second-generation ALK tyrosine kinase inhibitors (ALK-TKIs). The study found that co-occurring genetic alterations, particularly the loss of CDKN2A/B, were associated with a poorer prognosis in metastatic ALK-positive NSCLC patients. CDKN2A/B loss was the second most frequent co-alteration identified in ALK-positive NSCLC patients and was associated with worse progression-free survival (PFS) and overall survival (OS) even after adjusting for other known prognostic factors such as TP53 mutations and the presence of brain metastases. In addition, CDKN2A/B loss was strongly associated with a higher risk of brain metastasis at diagnosis and during the course of the disease. The study suggests that identifying patients with an unfavorable genetic profile and earlier mechanisms of resistance could guide clinicians to optimize treatment strategies and explore potential drug combinations to overcome resistance in this group of patients. The results highlight the importance of considering concurrent genetic alterations in the management of ALK-positive NSCLC patients and may help personalize treatment approaches for better outcomes.

Asset Subtitle

Oscar ARRIETA

Meta Tag

Speaker Oscar ARRIETA

Topic Metastatic NSCLC: Targeted Therapy - FUSIONS

Keywords

Latin American cancer centers

prognostic role

genetic alterations

ALK-positive non-small cell lung cancer

second-generation ALK tyrosine kinase inhibitors

CDKN2A/B loss

metastatic ALK-positive NSCLC patients

progression-free survival

overall survival

TP53 mutations